electroCore, Inc. (ECOR) Stock Analysis and Metrics

electroCore

NASDAQ: ECOR

$6.24 ▼ -0.13 (-1.96%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap56,941.08

P/E-0.03

P/S0.00

Div. Yield0.00

Total Debt (Qtr)6.69 Mn

Revenue Growth (1y) (Qtr)42.64

Add ratio to table…

About

electroCore, Inc. is a bioelectronic technology company that develops and markets noninvasive bioelectronic technologies to improve health and quality of life. The company offers prescription medical devices for treating primary headache and fibromyalgia, and consumer wellness products for general health and human performance. Its prescription products include gammaCore, a handheld vagus nerve stimulation device cleared for migraine and cluster headache, and Quell Fibromyalgia, a wearable neuromodulation device authorized to reduce fibromyalgia symptoms. Consumer wellness products consist of Truvaga, a handheld device for general wellbeing, and TACSTIM, a nonprescription vagus nerve stimulation device sold to military and professional users. electroCore's capabilities cover product development, regulatory compliance, sales and marketing, assembly, intellectual property management, and customer support. The company operates from its facility in Rockaway, New Jersey, serving customers in the United States and select overseas markets.

electroCore generates revenue from the sale of its prescription medical devices and nonprescription wellness products. Prescription product sales come from gammaCore and Quell Fibromyalgia, distributed through prescriptions written by health care providers and filled at specialty pharmacies, government channels, or directly from the company's facility in Rockaway, New Jersey. After the initial prescription, patients can obtain refills with a prescription authorization for certain gammaCore products. Consumer wellness product sales derive from Truvaga and TACSTIM, sold direct to consumer through the company's ecommerce website, online retailers such as Best Buy and Rehabmart, and select employment benefit plans. The company also generates revenue from replacement electrodes for its discontinued over the counter Quell OTC product, which remains available to existing customers. Government contracts, particularly with the United States Department of Veterans Affairs and the United Kingdom National Health Service, represent a significant portion of total sales, with the VA accounting for over 70% of revenue in 2025. Additional revenue comes from open market sales to individual federal facilities and from distribution partners serving military and civilian healthcare systems. The distribution agreement with Lovell Government Services facilitates access to federal procurement channels such as the Federal Supply Schedule, GSA Advantage, VA Distribution and Pricing Agreement, and Defense Logistics Agency's ECAT system. Sales to the United Kingdom National Health Service are conducted under the MedTech Funding Mandate for cluster headache, providing a reimbursement pathway within the NHS.

The company operates through the following segments.

• Prescription Medical Devices: This segment includes gammaCore and Quell Fibromyalgia products, which are FDA cleared prescription medical devices for treating primary headache conditions such as migraine and cluster headache and for reducing fibromyalgia symptoms, sold through prescriptions via specialty pharmacies, government channels, and direct to consumer channels.

• Consumer Wellness Products: This segment includes Truvaga and TACSTIM handheld devices marketed as general wellness and human performance products under FDA low risk guidance, sold direct to consumer through ecommerce sites, retail partners such as Best Buy and Rehabmart, and affiliate influencers who promote the brands through social media and content partnerships.

electroCore operates in the competitive bioelectronic technology and wellness device markets, facing pharmaceutical neuromodulation companies and emerging consumer technology firms. In the prescription headache segment, gammaCore competes with device based therapies such as CEFALY, Nerivio, and Savi Dual, as well as pharmacological treatments including triptans, CGRP antagonists, and botulinum toxin injections. For fibromyalgia, Quell Fibromyalgia competes within the broader transcutaneous electrical nerve stimulation market alongside numerous low cost TENS units and prescription medications like pregabalin, duloxetine, and milnacipran. The company's competitive advantages stem from its proprietary high frequency burst waveform technology that stimulates vagus nerve fibers through the skin, its suite of FDA clearances and Breakthrough Device designations for multiple indications, and an expanding patent portfolio that exceeded 215 patents and applications as of December 2025. Additionally, electroCore benefits from its early mover status in the external vagus nerve stimulator regulatory category, its strong intellectual property protection, and its established government contracts with the United States Department of Veterans Affairs and the United Kingdom National Health Service, which provide recurring revenue streams and barriers to entry for rivals. While large technology companies such as Apple, Amazon, and Google have entered the general wellness space with substantial resources, electroCore differentiates itself through its focus on clinically validated neurostimulation technology and its regulatory cleared medical device status.

electroCore's customer base is divided between government healthcare purchasers and direct to consumer wellness buyers. The company's two largest customers by revenue are the United States Department of Veterans Affairs and the United Kingdom National Health Service, which together accounted for approximately 75% of total revenue in 2025, with the VA contributing about 71.2% and the NHS about 4.4%. In addition to these national agencies, electroCore sells its prescription gammaCore and Quell Fibromyalgia products to individual facilities within the Veterans Health Administration, Military Health System, and Indian Health Services through its Federal Supply Schedule contract and through distribution partners such as Lovell Government Services. The company also serves patients who obtain prescriptions for its medical devices via specialty pharmacies and through the direct to consumer channel for its Truvaga and TACSTIM wellness products, which are purchased by individuals seeking general health improvement and performance enhancement. Furthermore, electroCore maintains relationships with online retailers, affiliate marketers, and employment benefit plans that distribute its consumer wellness products to a broad base of health conscious consumers.

Investment Thesis

▲ Bull case

electroCore, Inc. is positioned to capitalize on its deepening penetration within the VA system, where current device penetration of approximately 2.5% among headache sufferers indicates substantial untapped demand given the underlying population growth and high comorbidity rates with PTSD and TBI. The VA prescription device revenue grew 48% year over year to $7.9 million in Q1 FY26, with Quell surpassing $1 million in quarterly sales for the first time and cumulative Quell revenue reaching $2.5 million since the NeuroMetrix acquisition. With Mike Fox’s 35 years of federal channel experience now driving a strategy focused on facility depth—more prescribers per site and more patients per prescriber—the company is shifting from broad distribution to intensive utilization, which could unlock significant upside as the VA continues to emphasize non-opioid first-line treatment for chronic pain. This operational shift, combined with the expanding evidence base from studies like the JAMA Network Open analysis showing 8.2% of male and 30.1% of female veterans reporting migraine history, supports a multi-year runway for gammaCore and Quell adoption that remains vastly underpenetrated relative to the addressable market.
The consumer wellness channel, led by TruVega, is demonstrating improving unit economics and scalable growth potential, with Q1 FY26 revenue reaching $1.6 million, up 44% year over year, and TruVega contributing $1.5 million, up 38% year over year. The company’s deliberate focus on efficiency over pure top-line growth yielded a 14% improvement in return on advertising spend (ROAS) to approximately 2.37, driven by a strategic shift toward affiliate and influencer partnerships targeting consumers already interested in vagus nerve stimulation. This optimization suggests that as TruVega scales, particularly following its January 2026 UK launch and planned international expansion, the business can achieve profitable customer acquisition at scale. Independent industry research projecting a low double-digit CAGR for the global noninvasive vagus nerve stimulation market through 2030, supported by aging demographics and rising consumer awareness, provides a structural tailwind that electroCore is well-positioned to capture via its science-backed, direct-to-consumer approach, especially as it develops a next-generation mobile platform to enable recurring revenue and deeper engagement.
electroCore’s path to profitability is being reinforced by operating leverage evident in Q1 FY26 results, where 43% revenue growth to $9.6 million coincided with an 87% gross margin (a 200 basis point improvement year over year) and a 24% improvement in adjusted EBITDA loss to $2.3 million, despite $1.9 million in nonrecurring leadership transition costs. Excluding these one-time expenses, the adjusted EBITDA loss would have been substantially lower, highlighting the underlying scalability of the business model. With Mike Fox prioritizing operating discipline to ensure incremental revenue translates to incremental bottom line, and with gross margins in the mid-80s providing a strong foundation, the company is positioned to achieve profitability as revenue growth continues. The reaffirmed full-year FY26 guidance of approximately 30% growth—translating to $9–10 million in incremental revenue versus the $32 million FY25 base—is underpinned by continued VA prescription growth, TruVega efficiency gains, and upcoming contributions from Quell Relief relaunch and TACSTIM federal expansion, all of which suggest the market may be underestimating the near-term inflection point in profitability driven by operating leverage and channel diversification.

electroCore, Inc. is positioned to capitalize on its deepening penetration within the VA system, where current device penetration of approximately 2.5% among headache sufferers indicates substantial untapped demand given the underlying population growth and high comorbidity rates with PTSD and TBI. The VA prescription device revenue grew 48% year over year to $7.9 million in Q1 FY26, with Quell surpassing $1 million in quarterly sales for the first time and cumulative Quell revenue reaching $2.5 million since the NeuroMetrix acquisition. With Mike Fox’s 35 years of federal channel experience now driving a strategy focused on facility depth—more prescribers per site and more patients per prescriber—the company is shifting from broad distribution to intensive utilization, which could unlock significant upside as the VA continues to emphasize non-opioid first-line treatment for chronic pain. This operational shift, combined with the expanding evidence base from studies like the JAMA Network Open analysis showing 8.2% of male and 30.1% of female veterans reporting migraine history, supports a multi-year runway for gammaCore and Quell adoption that remains vastly underpenetrated relative to the addressable market.
The consumer wellness channel, led by TruVega, is demonstrating improving unit economics and scalable growth potential, with Q1 FY26 revenue reaching $1.6 million, up 44% year over year, and TruVega contributing $1.5 million, up 38% year over year. The company’s deliberate focus on efficiency over pure top-line growth yielded a 14% improvement in return on advertising spend (ROAS) to approximately 2.37, driven by a strategic shift toward affiliate and influencer partnerships targeting consumers already interested in vagus nerve stimulation. This optimization suggests that as TruVega scales, particularly following its January 2026 UK launch and planned international expansion, the business can achieve profitable customer acquisition at scale. Independent industry research projecting a low double-digit CAGR for the global noninvasive vagus nerve stimulation market through 2030, supported by aging demographics and rising consumer awareness, provides a structural tailwind that electroCore is well-positioned to capture via its science-backed, direct-to-consumer approach, especially as it develops a next-generation mobile platform to enable recurring revenue and deeper engagement.
electroCore’s path to profitability is being reinforced by operating leverage evident in Q1 FY26 results, where 43% revenue growth to $9.6 million coincided with an 87% gross margin (a 200 basis point improvement year over year) and a 24% improvement in adjusted EBITDA loss to $2.3 million, despite $1.9 million in nonrecurring leadership transition costs. Excluding these one-time expenses, the adjusted EBITDA loss would have been substantially lower, highlighting the underlying scalability of the business model. With Mike Fox prioritizing operating discipline to ensure incremental revenue translates to incremental bottom line, and with gross margins in the mid-80s providing a strong foundation, the company is positioned to achieve profitability as revenue growth continues. The reaffirmed full-year FY26 guidance of approximately 30% growth—translating to $9–10 million in incremental revenue versus the $32 million FY25 base—is underpinned by continued VA prescription growth, TruVega efficiency gains, and upcoming contributions from Quell Relief relaunch and TACSTIM federal expansion, all of which suggest the market may be underestimating the near-term inflection point in profitability driven by operating leverage and channel diversification.

▼ Bear case

electroCore, Inc. faces significant execution risks in its federal channel expansion strategy, particularly as Mike Fox’s focus on shifting from facility breadth to depth in the VA system may not translate to predictable revenue growth due to entrenched bureaucratic hurdles, lengthy procurement cycles, and the challenge of changing prescribing behaviors across decentralized medical centers. Despite having products in approximately 200 VA facilities, the company acknowledged that the majority of new patients identified and prescribed in Q1 were not spread across the country as expected, indicating persistent difficulties in achieving consistent utilization even where distribution exists. The reliance on facility depth—requiring more prescribers per site and more patients per prescriber—introduces variability and dependence on individual clinician engagement, which is difficult to scale and measure, especially given the VA’s standardization requirements and the need for top-down support at the VISN or national level. This operational complexity could result in slower-than-anticipated penetration, undermining the assumption that current 2.5% VA headache market penetration implies a long, linear runway for growth, especially if reimbursement policies or clinical guidelines do not evolve rapidly enough to support broader adoption.
The consumer wellness channel, while showing improved ROAS, remains vulnerable to high customer acquisition costs, volatile marketing effectiveness, and limited differentiation in an increasingly crowded market for non-pharmacologic wellness solutions, with TruVega’s return rates persistently in the 12% to 15% range signaling potential dissatisfaction or limited perceived efficacy among users. Although the company highlighted a shift toward affiliate and influencer partnerships—citing Miranda Kerr’s co-marketing opportunity—as a driver of improved efficiency, this approach introduces dependency on third-party promoters whose audience alignment and messaging consistency may not be sustainable or scalable over time. Furthermore, the global noninvasive vagus nerve stimulation market’s projected low double-digit CAGR through 2030 is contingent on regulatory and clinical shifts toward non-opioid pain management, which may not materialize at the expected pace, and electroCore’s TruVega product, positioned as a general wellness device rather than a prescribed therapeutic, faces stiffer competition from established players in the broader wellness and wearable tech space, limiting its ability to capture meaningful share without significant and ongoing marketing investment that could erode the recently improved unit economics.

electroCore, Inc. faces significant execution risks in its federal channel expansion strategy, particularly as Mike Fox’s focus on shifting from facility breadth to depth in the VA system may not translate to predictable revenue growth due to entrenched bureaucratic hurdles, lengthy procurement cycles, and the challenge of changing prescribing behaviors across decentralized medical centers. Despite having products in approximately 200 VA facilities, the company acknowledged that the majority of new patients identified and prescribed in Q1 were not spread across the country as expected, indicating persistent difficulties in achieving consistent utilization even where distribution exists. The reliance on facility depth—requiring more prescribers per site and more patients per prescriber—introduces variability and dependence on individual clinician engagement, which is difficult to scale and measure, especially given the VA’s standardization requirements and the need for top-down support at the VISN or national level. This operational complexity could result in slower-than-anticipated penetration, undermining the assumption that current 2.5% VA headache market penetration implies a long, linear runway for growth, especially if reimbursement policies or clinical guidelines do not evolve rapidly enough to support broader adoption.
The consumer wellness channel, while showing improved ROAS, remains vulnerable to high customer acquisition costs, volatile marketing effectiveness, and limited differentiation in an increasingly crowded market for non-pharmacologic wellness solutions, with TruVega’s return rates persistently in the 12% to 15% range signaling potential dissatisfaction or limited perceived efficacy among users. Although the company highlighted a shift toward affiliate and influencer partnerships—citing Miranda Kerr’s co-marketing opportunity—as a driver of improved efficiency, this approach introduces dependency on third-party promoters whose audience alignment and messaging consistency may not be sustainable or scalable over time. Furthermore, the global noninvasive vagus nerve stimulation market’s projected low double-digit CAGR through 2030 is contingent on regulatory and clinical shifts toward non-opioid pain management, which may not materialize at the expected pace, and electroCore’s TruVega product, positioned as a general wellness device rather than a prescribed therapeutic, faces stiffer competition from established players in the broader wellness and wearable tech space, limiting its ability to capture meaningful share without significant and ongoing marketing investment that could erode the recently improved unit economics.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Contract with Customer, Sales Channel Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Contract with Customer, Sales Channel Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password